Amgen announced a landmark clinical trial demonstrating that its PCSK9 inhibitor, Repatha, significantly reduces the incidence of heart disease events in patients without prior cardiovascular problems. The study, encompassing 12,000 patients, highlights Repatha's ability to lower LDL cholesterol and prevent first-time heart attacks and strokes, potentially extending treatment access to a vast population. This follows earlier approvals of Repatha for secondary prevention and signals a resurgence of PCSK9 inhibitors despite earlier commercial setbacks. Experts note the substantial unmet need in achieving LDL-C targets worldwide.